Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma

PURPOSE: Programmed death ligand 1 (PD-L1) is widely used for predicting immune checkpoint inhibitors but has a limited effect on predicting clinical response. The aim of this study was to examine the prognostic value and PD-1 inhibitor therapeutic efficiency of SNX20 in lung adenocarcinoma. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Linwei, Li, Li, Huang, Chunye, Huang, Shanshan, Deng, Jun, Xiong, Jianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555289/
https://www.ncbi.nlm.nih.gov/pubmed/33116590
http://dx.doi.org/10.2147/OTT.S262909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555289/
https://www.ncbi.nlm.nih.gov/pubmed/33116590
http://dx.doi.org/10.2147/OTT.S262909

Ejemplares similares